Phase II Study of Regorafenib as Single Agent for the Treatment of Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab

Trial Profile

Phase II Study of Regorafenib as Single Agent for the Treatment of Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms PREVIUM
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 May 2016 Status changed from recruiting to completed.
    • 01 Oct 2015 Trial design presented at the 17th World Congress on Gastrointestinal Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top